Steven Young, Raseen Tariq, John Provenza, Sanjaya K. Satapathy, Kamal Faisal, Abhijit Choudhry, Scott L. Friedman, Ashwani K. Singal – 21 May 2020 – Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among individuals who are lean (normal body mass index) is unclear. Published data from studies comparing lean with obese NAFLD or with healthy subjects on prevalence, comorbidities, liver chemistry and histology, and metabolic/inflammatory markers were analyzed.

K. Rajender Reddy – 21 May 2020

K. Rajender Reddy – 21 May 2020

Esperance A. K. Schaefer, Ashwini Arvind, Patricia P. Bloom, Raymond T. Chung – 21 May 2020

George Lau, John W. Ward – 21 May 2020

Olga Protchenko, Ethan Baratz, Shyamalagauri Jadhav, Fengmin Li, Minoo Shakoury‐Elizeh, Oksana Gavrilova, Manik C. Ghosh, James E. Cox, J. Alan Maschek, Vladimir A. Tyurin, Yulia Y. Tyurina, Hülya Bayir, Allegra T. Aron, Christopher J. Chang, Valerian E. Kagan, Caroline C. Philpott – 21 May 2020

Ganesh Gunasekaran, Yuki Bekki, Vennis Lourdusamy, Myron Schwartz – 21 May 2020 – Hepatobiliary cancers which include hepatocellular carcinoma (HCC) and biliary tract cancers (i.e., cholangiocarcinoma and gallbladder carcinoma) are associated with significant morbidity and mortality based on the stage of the disease at presentation. With improved screening for hepatobiliary malignancies in patients with risk factors and with widespread use of laparoscopic cholecystectomy, hepatobiliary malignancies, including incidental diagnosis of gallbladder carcinoma, are on the rise.

Matthew R. Kappus, Kara Wegermann, Erol Bozdogan, Yuval A. Patel, Gemini Janas, Erin Shropshire, Alice Parish, Donna Niedzwiecki, Andrew J. Muir, Mustafa Bashir – 20 May 2020 – The aim of this study is to validate a proposed definition of sarcopenia in predicting wait‐list mortality. We retrospectively evaluated 355 adults (age ≥18 years) with cirrhosis listed for first‐time LT from January 1, 2010, to April 1, 2018 from our center. Demographic, laboratory, and outcome data were collected in conjunction with computed tomography scans performed within 3 months of listing.

Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, Myron Schwartz, Tim Meyer, Peter R. Galle, Riccardo Lencioni, Tim F. Greten, Masatoshi Kudo, Sumithra J. Mandrekar, Andrew X. Zhu, Richard S. Finn, Lewis R. Roberts, AASLD Panel of Experts on Trial Design in HCC – 20 May 2020

Extrahepatic manifestations of HCV contribute to its increased overall mortality rate in those infected relative to those who aren’t; associated cardiovascular, neoplastic and renal manifestations can contribute significantly to a patient’s truncated lifespan beyond liver-related morbidity. This webinar will address the recognition and the treatment of extrahepatic manifestations of chronic HCV infection. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Miklos Z. Molnar Dr. Miklos Z.